Showing 2371-2380 of 5771 results for "".
- Aerie Pharmaceuticals Announces Acceptance of Its Investigational NDA for AR-1105 (Dexamethasone Intravitreal Implant)https://modernod.com/news/aerie-pharmaceuticals-announces-acceptance-of-its-investigational-nda-for-ar-1105-dexamethasone-intravitreal-implant/2476183/Aerie Pharmaceuticals announced that the FDA has reviewed the investigational new drug application (IND) for AR-1105 (dexamethasone intravitreal implant) and it is now in effect, allowing Aerie to initiate human studies in the treatment of macular edema due to retinal vein occlusion (RVO). The IN
- Wize Pharma Announces Publication of LOA2 Data on Treatment of Moderately Severe Sjögren’s Syndrome-Related Dry Eyehttps://modernod.com/news/wize-pharma-announces-publication-of-loa2-data-on-treatment-of-moderately-severe-sjogrens-syndrome-related-dry-eye/2476200/Wize Pharma announced publication of data generated in an investigator initiated study conducted in Hungary during 2016, entitled “Treatment of Moderately Severe Sjögren’s Syndrome-Related Dry Eye without Immunomodulation: A Self-Controlled, Unmasked S
- Allergan Announces Positive 3-Month Topline Results from Second Phase 3 Study of Bimatoprost SR Implant for Lowering IOPhttps://modernod.com/news/allergan-announces-positive-3-month-topline-results-from-second-phase-3-study-of-bimatoprost-sr-implant-for-lowering-iop/2476215/Allergan announced positive 3-month topline results from the second pivotal clinical trial of Bimatoprost SR, a first-in-class sustained-release, biodegradable implant for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. Positive results from the first phase 3 tri
- Kala Pharmaceuticals Announces the Launch of Inveltyshttps://modernod.com/news/kala-pharmaceuticals-announces-the-launch-of-inveltys-and-the-hiring-of-a-specialty-ophthalmology-sales-organization/2476217/Kala Pharmaceuticals announced the launch of Inveltys (loteprednol etabonate ophthalmic suspension) 1%, the first and only twice-daily ocular corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery. Kala also announced the hiring of the specialty
- Aerie Pharmaceuticals Announces Positive Topline Results of Netarsudil Ophthalmic Solution in Pilot Phase 2 Studyhttps://modernod.com/news/aerie-pharmaceuticals-announces-positive-topline-results-of-netarsudil-ophthalmic-solution-in-pilot-phase-2-study/2476219/Aerie Pharmaceuticals announced the topline results of its pilot phase 2 study of netarsudil ophthalmic solution in a Japanese-American population. The study was designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support the potential regu
- Bausch + Lomb Announces Health Canada Approval Of Vyzulta for the Treatment of Glaucomahttps://modernod.com/news/bausch-lomb-announces-health-canada-approval-of-vyzulta-for-the-treatment-of-glaucoma/2476223/Bausch + Lomb announced that Health Canada issued a Notice of Compliance approving Vyzulta (latanoprostene bunod ophthalmic solution, 0.024%) for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. Vyzulta is the first prostaglandin analog with one of its metabolites
- Dompé Announces First Treatment with Oxervate Eye Drops for Neurotrophic Keratitis (NK)https://modernod.com/news/dompe-announces-first-treatment-with-oxervate-eye-drops-for-neurotrophic-keratitis-nk/2476224/Dompé announced the first treatment of a patient with Oxervate eye drops (cenegermin-bkbj) in the United States. Oxervate was approved by the FDA in August 2018 as the first drug specifically indicated to treat neurotrophic keratitis
- American Vision Partners Announces Partnership With Las Vegas’ Abrams Eye Institutehttps://modernod.com/news/american-vision-partners-announces-partnership-with-las-vegas-abrams-eye-institute/2476225/American Vision Partners, an eyecare practice management organization, has established a partnership with Las Vegas-based Abrams Eye Institute, marking its initial move into the Nevada market, according to an announcement this week, as
- Ophthotech Announces the Addition of Calvin W. Roberts, MD, to Its Board of Directorshttps://modernod.com/news/ophthotech-announces-the-addition-of-ophthalmic-industry-leader-calvin-w-roberts-md-to-its-board-of-directors/2476231/Ophthotech Corporation announced the election of Calvin (Cal) W. Roberts, MD, Senior Vice President and Chief Medical Officer, Eye Care at Bausch Health Companies, and Clinical Professor of Ophthalmology at Weill Medical College of Cornell University, to its Board of Directors, effective as of Ja
- Ocular Therapeutix Announces Completion of Debt Refinancinghttps://modernod.com/news/ocular-therapeutix-announces-completion-of-debt-refinancing/2476236/Ocular Therapeutix announced that it has closed a refinancing of its existing debt by entering into a new $25 million term loan with MidCap Financial and Silicon Valley Bank. The 5-year term loan facility allows for an expansion of the company’s prior $18 million credit facility to $25 mil